MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.
Validation Data on 60 Patients published in Cancer Genetics
CHICAGO, July 7, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the development...
NORTH CHICAGO, Ill., June 25, 2025 /PRNewswire/ -- UP Oncolytics, a neuro-oncology biotechnology company based in Milwaukee and a spin-out of the Advocate Aurora Research...
INRS Professor receives $1.2M to advance glioblastoma research
LAVAL, QC, June 20, 2025 /CNW/ - Professor Maya Saleh, a world-renowned expert in immuno-oncology at the Institut national...